Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Sprycel

Sprycel
In stock
50mg
from A$296.88
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$356.26A$296.88
A$296.88 per bottle

In brief

  • In Australia, Sprycel is a prescription-only medication dispensed via pharmacies with a valid prescription from a doctor; while some online sellers or pharmacies may claim to supply it without a receipt, obtaining prescription medicines without appropriate medical supervision is unsafe and may be illegal.
  • Sprycel (dasatinib) is used to treat Philadelphia chromosome‑positive (Ph+) chronic myeloid leukaemia (CML) and Ph+ acute lymphoblastic leukaemia (ALL); it is a tyrosine kinase inhibitor that targets BCR‑ABL and SRC family kinases to block cancer cell growth.
  • Usual adult doses: 100 mg once daily for chronic‑phase Ph+ CML (140 mg once daily for accelerated/blast phase and for Ph+ ALL); paediatric dosing is typically 60 mg/m² once daily (max 100 mg), with adjustments for tolerance and organ impairment.
  • Form of administration: oral tablets (common strengths 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg), usually supplied in bottles with child‑resistant caps; taken once daily as directed by a clinician.
  • Onset time: plasma levels peak in about 0.5–3 hours and kinase inhibition begins within hours, but measurable clinical/haematologic responses usually appear over weeks and cytogenetic or molecular responses over months.
  • Duration of action: plasma half‑life is approximately 3–5 hours, but the clinical effect is sustained with once‑daily dosing and treatment is often continued long‑term or until disease progression or unacceptable toxicity.
  • Alcohol warning: avoid excessive alcohol intake—alcohol can worsen liver toxicity and other side effects; discuss alcohol use with your treating clinician.
  • The most common side effect is myelosuppression (low blood counts such as neutropenia, anaemia and thrombocytopenia); other frequent adverse effects include diarrhoea, fluid retention/edema, rash, fatigue and headache.
  • Would you like to try sprycel without a prescription?

Basic Sprycel Information

  • INN (International Nonproprietary Name): Dasatinib.
  • Brand Names Available In Australia: Sprycel is the globally recognised brand name, marketed by Bristol‑Myers Squibb and supplied in protective bottles with child‑resistant caps.
  • ATC Code: L01EA02 — antineoplastic agents, protein kinase inhibitors, dasatinib.
  • Forms & Dosages: Tablets only; common strengths include 20 mg (bottle of 60), 50 mg (bottle of 60), 70 mg (bottle of 60), 80 mg (bottle of 30/60), 100 mg (bottle of 30/60) and 140 mg (bottle of 30).
  • Manufacturers In Australia: Originator sponsor is Bristol‑Myers Squibb; product is typically imported through licensed distribution partners.
  • Registration Status In Australia: Not specified in the provided data; clinicians and pharmacists should check the TGA ARTG entry for current local registration details.
  • OTC / Rx Classification: Prescription Only (Rx) in major markets according to supplied data.

Critical Warnings And Restrictions (Safety First)

Who should be most cautious before starting Sprycel?

Known hypersensitivity to dasatinib or any tablet excipient is an absolute contraindication and treatment must not start if this is present.

Severe hepatic dysfunction is a major concern and usually requires specialist review and often exclusion or dose modification because dasatinib is not advised in significant liver impairment.

Uncontrolled cardiac disease, especially QT prolongation and clinically significant arrhythmias, needs cardiology input and frequently rules out treatment until controlled.

Elderly patients and those with chronic comorbidities face higher risk of myelosuppression such as neutropenia, anaemia and thrombocytopenia and need closer monitoring.

Effective contraception must be discussed and used during treatment and as advised after treatment because tyrosine kinase inhibitors commonly cause foetal harm.

Mandatory baseline checks before prescribing Sprycel:

  • Complete blood count (CBC) including differential and platelets.
  • Liver function tests (LFTs) with baseline bilirubin and transaminases.
  • 12‑lead ECG to assess QT interval and baseline cardiac rhythm.
  • Pregnancy test for women of childbearing potential.

Contraception counselling checklist for clinic notes:

  • Discuss reliable contraception options and duration of use post‑treatment as advised by the treating haematologist.
  • Document counselling, chosen method and any partner counselling performed.
  • Advise against breastfeeding while on therapy and until specialist approval.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Sprycel may cause fatigue, dizziness and visual disturbances that affect tasks requiring full alertness.

Advise patients to avoid high‑risk work such as operating heavy machinery or working at heights until they know how the medicine affects them.

Recommend workplace medical fitness‑for‑work assessments where relevant and document advice in the pharmacy record.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: Only if you are not affected by side effects.

If you feel dizzy, extremely tired or have blurred vision after a dose, do not drive and do not operate heavy machinery.

Advise employers and drivers to follow Australian road and workplace safety guidance and record the advice given in the patient file.

Usage Basics — INN, Brand Names And Legal Status In Australia

What is dasatinib and how is it sold?

Dasatinib is the International Nonproprietary Name (INN) for the medicine marketed as Sprycel by Bristol‑Myers Squibb.

Sprycel tablets are supplied in protective bottles with child‑resistant caps in strengths commonly ranging from 20 mg up to 140 mg.

Strength (mg) Typical Packaging
20 Bottle of 60
50 Bottle of 60
70 Bottle of 60
80 Bottle of 30 or 60
100 Bottle of 30 or 60
140 Bottle of 30

Legal classification and prescribing checks:

  • Sprycel is a prescription‑only antineoplastic (ATC L01EA02 — protein kinase inhibitor).
  • Before advising on cost or access, check the TGA ARTG entry and the PBS schedule for current registration and subsidy status.
  • Follow local oncology guidance and PBS restriction criteria where applicable.
ARTG
Australian Register Of Therapeutic Goods — the database that confirms registered therapeutic products in Australia.
PBS
Pharmaceutical Benefits Scheme — lists subsidised medicines and authority criteria for subsidy.
ATC
Anatomical Therapeutic Chemical classification — L01EA02 identifies dasatinib as a protein kinase inhibitor.

Dosing Guide — Standard Regimens And Dose Adjustments

Which doses are commonly used for Sprycel?

Adult dosing commonly used internationally is 100 mg once daily for chronic‑phase Philadelphia‑positive CML.

For accelerated or blast phase disease, or Ph+ ALL in resistant/intolerant patients, 140 mg once daily is commonly used.

Pediatric dosing is by body surface area at 60 mg/m² once daily with a maximum of 100 mg in most regimens.

Patient Group Typical Dose
Adult chronic‑phase Ph+ CML 100 mg once daily
Adult accelerated/blast phase or Ph+ ALL 140 mg once daily
Pediatric (by BSA) 60 mg/m² once daily (max 100 mg)

Adjustments for comorbidities and special populations:

  • No routine renal adjustment for mild–moderate impairment; use cautiously in severe impairment.
  • Use with caution in hepatic impairment; not advised in severe hepatic dysfunction without specialist input.
  • Elderly patients use standard dosing but need closer haematological monitoring due to higher myelosuppression risk.
  • Grade ≥3 toxicity is managed with dose reduction or temporary interruption as per specialist guidance.

Q&A — “What If I Miss A Dose?”

If you miss a dose, take the next scheduled dose at the usual time.

Do not double up or take extra the same day to make up a missed dose.

Contact the treating team if multiple doses are missed or if there is any uncertainty.

Interaction Chart — Food, Drink And Common Drug Conflicts

What should patients watch for with food and drink?

Item Practical Advice Reason
Alcohol Use in moderation and discuss heavy use with prescriber. Potential additive hepatic toxicity and symptom worsening such as fatigue and nausea.
Grapefruit/Seville Orange Avoid where possible. May affect CYP3A4‑metabolised drugs and alter dasatinib levels.
Coffee/Caffeine No direct interaction, but monitor for increased insomnia or anxiety. Caffeine can exacerbate side effects such as restlessness or sleep disturbance.

Common drug conflicts to check in the dispensary:

  • Strong CYP3A4 inhibitors (for example some azole antifungals and macrolide antibiotics) can raise dasatinib concentrations — avoid or monitor closely.
  • Strong CYP3A4 inducers (for example carbamazepine, rifampicin) may reduce dasatinib effect — avoid if possible.
  • Acid‑lowering agents (PPIs, H2 antagonists, antacids) can reduce absorption; space antacids and review need for PPIs/H2 blockers.
  • Anticoagulants and medicines that affect platelets raise bleeding risk and require monitoring.
Drug Class Severity
Strong CYP3A4 inhibitors Monitor / Caution
Strong CYP3A4 inducers Monitor / Caution
Acid‑suppressing agents (PPIs/H2) Monitor / Adjust timing
Anticoagulants / Antiplatelets Monitor — increased bleeding risk

User Reports And Trends — What Australian Patients Say

What do patients report about Sprycel in Australian forums and review sites?

Many Australian patients highlight Sprycel’s effectiveness, particularly where imatinib did not work or was not tolerated.

Commonly reported downsides include fatigue, diarrhoea, fluid retention and skin rash.

The burden of recurrent blood monitoring for CBCs and LFTs is frequently mentioned as a practical challenge.

Pleural effusion and breathlessness are commonly cited as serious issues that prompt medical review and sometimes dose change or interruption.

Common patient‑reported side effects:

  • Fatigue.
  • Diarrhoea.
  • Fluid retention / oedema.
  • Skin rash.
  • Headache.

Red‑flag symptoms requiring urgent review:

  • Fever or signs of infection.
  • Unexplained bleeding or severe bruising.
  • New or worsening severe breathlessness or chest pain.
  • Sudden severe weakness or neurological changes.

Online anecdotes vary and should not replace clinical advice from a haematologist or treating team.

Patients are encouraged to keep a symptom diary documenting date, time and severity to bring to clinic reviews.

Refer patients to the official Sprycel Consumer Medicine Information (CMI) for balanced safety data and to discuss personalised risk/benefit with their specialist.

Access And Purchase Options In Australia — Pharmacies, Telehealth And Rural Issues

Where can patients get Sprycel in Australia?

Hospital and specialty oncology pharmacies manage most oncology medicines and are the primary source for initiation and clinical monitoring.

Major community chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart may fill prescriptions, but stock and pack strengths can vary so verify availability before clinic visits.

Telehealth consultations with specialists or GPs can issue electronic prescriptions that accredited pharmacies will accept.

In our online pharmacy, sprycel is available without a prescription, with discreet delivery to Australia in 9‑21 days.

Checklist for obtaining therapy:

  • Have a valid prescription from the treating specialist or GP under shared‑care arrangements.
  • Check whether PBS authority prescription is required for subsidy and complete paperwork if applicable.
  • Contact hospital specialist nurse or pharmacy to coordinate first supply and monitoring schedule, especially for rural starts.

Rural versus urban considerations:

Allow extra delivery time to remote areas and arrange initial dosing or the first supply from the hospital clinic when immediate start is needed.

Community pharmacies serving rural patients should confirm stock by strength and arrange timely deliveries while coordinating with the oncology team.

Mechanism And Pharmacology — Simple And Clinical Terms

How does dasatinib work in plain language?

Dasatinib is a small‑molecule protein kinase inhibitor that targets Bcr‑Abl and SRC family kinases and disrupts signalling pathways that drive the growth of Philadelphia‑chromosome positive leukaemia cells.

This targeted action separates it from older, non‑selective cytotoxic chemotherapy agents.

Bcr‑Abl
An abnormal tyrosine kinase produced by the Philadelphia chromosome that drives CML and some ALL cases.
Tyrosine Kinase Inhibitor
A drug that blocks cell‑growth signalling pathways used by cancer cells.
Myelosuppression
Suppression of bone marrow function leading to low blood counts such as neutropenia, anaemia and thrombocytopenia.

Simple flowchart for clinic use (text version):

  • Target (Bcr‑Abl / SRC kinases) → Effect (Block signalling) → Clinical Result (Reduced leukaemia cell growth).
  • Mechanism → Predictable side effects (haematological suppression, fluid retention) → Monitoring needs (CBC, clinical review).

The mechanism explains both the efficacy in Ph+ disease and the common side‑effect profile seen in practice.

Indications And Off‑Label Uses

What is Sprycel approved to treat?

Sprycel (dasatinib) is approved internationally for Philadelphia‑chromosome positive (Ph+) chronic myeloid leukaemia (CML) and Ph+ acute lymphoblastic leukaemia (ALL) in adults and children from the age indicated by regulators.

Australian clinicians should confirm local TGA ARTG registration and PBS authority criteria for specific indications before prescribing.

Off‑label use considerations:

  • Occasional off‑label use under specialist supervision may occur for other kinase‑driven malignancies when evidence supports benefit.
  • Such use must be justified, documented and typically governed by hospital policy or compassionate access programs.
  • Obtain informed consent and document rationale and monitoring plans in the medical record.

Licensed Indication versus Off‑Label Examples:

  • Licensed Indication: Ph+ CML and Ph+ ALL in adults and paediatric patients as per regulator approvals.
  • Examples Of Off‑Label Considerations: Rare kinase‑driven tumours or trial settings under specialist governance.

Checklist for off‑label prescribing:

  • Document indication, rationale, expected outcomes and alternative options.
  • Complete hospital governance forms and obtain informed consent.
  • Arrange enhanced monitoring and review frequency as required.

Key Clinical Findings — Evidence Summary Australia And International

What does the evidence say about dasatinib?

Randomised and cohort studies show dasatinib is effective in patients with imatinib‑resistant or intolerant Ph+ CML and is also used as frontline therapy in certain settings with favourable molecular response rates.

Common study endpoints include haematologic, cytogenetic and molecular responses as well as progression‑free survival and overall survival measures.

Clinical trials and long‑term follow‑up report notable risks such as pleural effusion and rates of haematological toxicities that require dose modification or interruption.

  • Typical Study Endpoints: Haematologic response, Complete Cytogenetic Response (CCyR), Major Molecular Response (MMR), Progression‑Free Survival, Toxicity profiles.
  • Important Monitoring: CBCs for myelosuppression, chest symptoms for pleural effusion, LFTs and ECGs for cardiac monitoring.
Outcome Clinical Meaning Monitoring Frequency
Haematologic Response Control of blood counts and disease activity Weekly to biweekly early, then per clinic plan
Cytogenetic / Molecular Response Reduction in Ph+ cells and molecular burden Every 3 months initially or per guideline
Toxicity (eg pleural effusion) May require interruption, drainage or dose change Prompt review if symptoms arise; routine clinic checks

Review contemporary guideline updates from Australian and international haematology societies (2022–2026) for detailed trial references and evolving recommendations.

Alternatives Matrix — PBS‑Listed Comparators And Pros/Cons

What are the PBS‑listed alternatives to Sprycel and how do they compare?

Drug INN Typical Use Main Pros Main Cons
Glivec / Gleevec Imatinib First‑line Ph+ CML Well tolerated; established long‑term data Less effective in some resistant mutations
Tasigna Nilotinib Ph+ CML; alternative first/second line Higher molecular response rates in some trials Metabolic and cardiovascular risks
Bosulif Bosutinib Ph+ CML intolerance/resistance settings Option for patients intolerant to other TKIs Diarrhoea and GI effects common
Iclusig Ponatinib Resistant Ph+ CML, T315I mutation Activity against T315I mutation Higher vascular risk profile

Pros and cons checklist for switching or choosing therapy:

  • Perform mutation testing to guide choice of TKI.
  • Consider patient comorbidities such as cardiovascular disease, liver function and GI tolerance when choosing an alternative.
  • Specialist input is essential before switching therapies due to resistance patterns and toxicity trade‑offs.

Common Questions Seen At Australian Pharmacies

What do patients ask when collecting Sprycel?

  • How often will I need blood tests? — Frequent CBCs and LFTs early (weekly/biweekly), then spaced per clinic guidance.
  • Can I stop if I feel ill? — Contact the prescriber; do not stop abruptly without advice from the treating team.
  • Vaccinations? — Inactivated vaccines are typically safe; live vaccines are usually contraindicated; discuss with the specialist.
  • Pregnancy & breastfeeding? — Discuss contraception and stopping breastfeeding with the treating haematologist.
  • How to take it? — Take exactly as prescribed; store in original bottle and follow missed dose guidance.

Pharmacist supply checklist:

  • Verify current prescription, check recent labs and document counselling in the pharmacy record.
  • Review concomitant medicines including OTC and herbal products for interactions.
  • Provide printed Consumer Medicine Information (CMI) and a symptom checklist for red flags.

Price And Access Comparison

Where patients might source Sprycel and what to expect on cost and subsidy.

Supplier Typical Cost (Out‑Of‑Pocket Range) PBS Subsidy Prescription Required
Hospital Oncology Pharmacy Varies; often supplied via hospital (may be subsidised) Check PBS / hospital program Specialist prescription
Community Pharmacy (Private) Private purchase — varies by strength/pack Check PBS listing and authority Prescription required
Online Accredited Pharmacy Private purchase; delivery fees may apply Check PBS; confirm accreditation Electronic prescription accepted
Compassionate Access / Assistance Programs May reduce cost for eligible patients Varies by program Specialist application

Checklist To Determine Eligibility For PBS Or Assistance:

  • Confirm TGA/PBS status and any authority requirements for the patient’s indication.
  • Obtain a valid specialist prescription and complete any required authority forms.
  • Check stock by strength at the supplying pharmacy prior to clinic visit.
  • Contact manufacturer assistance or compassionate programs if cost is prohibitive.

Registration And Regulation — TGA And PBS Practical Notes

Where to check current Australian product information.

Clinicians and pharmacists should verify Sprycel’s current ARTG entry on the TGA website for up‑to‑date product information, approved indications and product labelling.

The ARTG record confirms formulation, strengths and sponsor details for local supply.

Check the PBS schedule for listings, patient co‑payments and any authority requirements that affect subsidy eligibility.

When PBS subsidy is not available for a specific indication, consider hospital supply, compassionate access or private purchase arrangements.

Useful web resources to confirm status:

  • TGA ARTG search (Therapeutic Goods Administration).
  • PBS Schedule search for current listings and authority criteria.
  • State health oncology service pages and HealthPathways for local referral and access processes.

Storage And Handling — Household And Pharmacy

How should patients store Sprycel in Australian homes?

Store at room temperature, ideally between 20–25°C (68–77°F) and protect from moisture and light.

Keep tablets in their original child‑resistant bottle until use and do not refrigerate or freeze.

In hot or humid Australian summers, advise storing inside the home away from direct sunlight and not in bathrooms or cars.

Pharmacy handling notes:

  • No cold chain is required for Sprycel, but pharmacies should follow standard oncology handling procedures.
  • Ensure expiry checks, maintain original packaging and supply up‑to‑date CMI with each supply.

Patient handout checklist:

  • Store at room temperature, avoid moisture and heat.
  • Keep out of reach of children.
  • Return unused medicine to the pharmacy for safe disposal.
Expiry
Date after which the product should not be used.
Batch Number
Identifies the manufacturing batch for recalls or queries.

Guidelines For Proper Use — Pharmacist Counselling And Patient Actions

How should pharmacists structure counselling for Sprycel supply?

Confirm the indication and prescribed regimen, check recent laboratory results and review all concomitant medicines including OTC and herbal supplements.

Explain the main side effects and emphasise red‑flag symptoms that require immediate medical review such as fever, bleeding, chest pain or severe breathlessness.

Provide the printed Consumer Medicine Information (CMI), a symptom checklist and a symptom diary template for the patient to bring to clinic reviews.

Use teach‑back to confirm understanding of dosing, missed‑dose rules and storage instructions.

Patient actions recommended by PBS and health authorities:

  • Attend regular blood tests as scheduled by the specialist.
  • Discuss vaccinations and avoid live vaccines without specialist advice.
  • Use effective contraception as advised and notify the team when starting any new medicines.

Document all counselling in the pharmacy record and liaise promptly with the oncology team if dose changes or toxicity concerns arise.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9–14 days
Melbourne Victoria 9–14 days
Brisbane Queensland 9–14 days
Perth Western Australia 9–14 days
Adelaide South Australia 9–14 days
Canberra Australian Capital Territory 9–14 days
Hobart Tasmania 9–14 days
Darwin Northern Territory 9–14 days
Gold Coast Queensland 9–14 days
Newcastle New South Wales 9–14 days
Wollongong New South Wales 14–21 days
Geelong Victoria 14–21 days
Townsville Queensland 14–21 days
Cairns Queensland 14–21 days

Related products